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Human papillomavirus (HPV) infection is well established as an etiological agent responsi-
ble for a number of pathologies affecting the stratiﬁed epithelia of skin and anogenital sites.
More recently, the infection by (mucosal) high-risk HPV types has also been found to be
causally associated with squamous cell carcinoma in the head and neck region (HNSCC),
especially in the oropharynx. Intriguingly, HPV-related oropharyngeal squamous cell carci-
nomas (OPSCC) represent a distinct clinical entity compared to HPV-negative tumors with
particular regard to treatment–response and survival outcome. The association between
HPV infection and OPSCC may therefore have important implications for the prevention
and/or treatment of OPSCC.The improved survival of patientswith HPV-related tumors also
raises the question, as towhether a better understanding of the underlying differencesmay
help to identify new therapeutic concepts that could be used in targeted therapy for HPV-
negative and improved therapy for HPV-positive cancers.This review summarizes the most
recent advances in our understanding of the molecular principles of HPV-related OPSCC,
mainly based on functional genomic approaches, but also emphasizes the signiﬁcant role
played by the tumormicroenvironment, especially the immune system, for improved clinical
outcome and differential sensitivity of HPV-related tumors to current treatment options.
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HPV INFECTION IN THE PATHOGENESIS AND PROGNOSIS
OF HNSCC
Head and neck squamous cell carcinoma (HNSCC) is one of the
most prevalent and lethal cancers worldwide (Argiris et al., 2008).
Despite recent advances in early detection, surgical techniques,
radiation and chemotherapeutic regimes (Temamet al., 2007; Sheu
et al., 2009), the survival rate and quality of life for patients with
HNSCC has only marginally improved over the past few decades
(Haddad and Shin, 2008; Masuda et al., 2011). There is a desper-
ate need for better biomarkers, to identify patients at high-risk for
treatment failure, as well as novel concepts for a more effective
and less toxic therapy for patients with advanced tumors (Hunter
et al., 2005; Leemans et al., 2011).
Head and neck squamous cell carcinoma has a strong epidemi-
ologic background (Rodriguez et al., 2004; D’Souza et al., 2007;
Furniss et al., 2009) including environmental and lifestyle fac-
tors. The major risk factors for HNSCC are tobacco and alcohol
abuse; however, the escalating incidence of oropharyngeal carci-
noma (oropharyngeal squamous cell carcinoma, OPSCC) are not
explained by increases in either smoking and alcohol consumption
suggesting that atypical behavioral and environmental factors are
also involved (Ernster et al., 2007). Importantly, a subgroup of
OPSCCs has causally been linked to infection with high-risk types
of humanpapillomavirus (HPV), especiallyHPV16 (Gillison et al.,
2008; Pai and Westra, 2009). HPV infection has been established
as a causative agent for almost 70% of OPSCCs and 20–25% of
all HNSCCs (Gillison et al., 2000; Begum et al., 2005; Kreimer
et al., 2005; Reimers et al., 2007; Hoffmann et al., 2010). In recent
years, HPV-related tumors have been shown to be a new tumor
entity in itself, with distinct clinical and histopathological features,
including younger median age, oropharyngeal primary anatomi-
cal site, small tumor size, high lymph node involvement, as well
as a lack of typical risk factors, and increasing incidence over the
last decades at variance with decreasing total HNSCC incidence.
Furthermore, HPV-related tumors do not show signiﬁcant kera-
tinization and they have a prominent basaloid morphology. The
differences between HPV-related and HPV-negative tumors have
been reviewed in several excellent recent reviews (Argiris et al.,
2008; Psyrri and Dimaio, 2008; Leemans et al., 2011).
Intriguingly, patients with a HPV-positive tumor have
improved performance status and a better prognosis compared
to HPV-negative patients, even though the former patients were
more likely to present with regional lymph node metastasis at
the time of diagnosis (Curado and Hashibe, 2009; Pai and Wes-
tra, 2009). In general, HPV-positive patients are highly curable
with ionizing radiation with or without chemotherapy, and have
better overall and disease-free survival compared to patients diag-
nosed with HPV-negative tumors (Figure 1) (Fakhry et al., 2008;
www.frontiersin.org April 2012 | Volume 2 | Article 36 | 1
Kostareli et al. HPV-related oropharyngeal squamous cell carcinomas
FIGURE 1 | Classification of HNSCC according to HPV tumor status.
HPV-related tumors are distinct from non-HPV-related tumors in biological
and clinical features, including response to radio- and chemotherapy and
clinical outcome.
Ang et al., 2010). However, in several studies HPV DNA-positive
OPSCCswere heterogeneous in both biological and clinical behav-
ior, possibly due to differences in viral load and/or viral oncogene
expression (Paz et al., 1997; Andl et al., 1998; Klussmann et al.,
2001; van Houten et al., 2001;Mellin et al., 2002;Wiest et al., 2002;
Braakhuis et al., 2004; Lindquist et al., 2007; Reimers et al., 2007;
Attner et al., 2010; Jung et al., 2010).
ALTERATIONS IN THE GENOME, EPIGENOME, AND
TRANSCRIPTOME OF HPV-RELATED TUMORS
Functional genome and transcriptome studies strongly suggest
that HPV-related HNSCCs comprise a disease entity that differs
from HPV-negative tumors in regard to distinct molecular char-
acteristics. In the past, several groups used comparative genomic
hybridization (CGH) to identify genomic imbalance in the patho-
genesis of HNSCCs, focusing on HPV-related and HPV-negative
tumors (Dahlgren et al., 2003; Smeets et al., 2006; Klussmann et al.,
2009; Wilting et al., 2009). Despite tumor-associated genomic
alterations, which are common in both groups, these studies
highlighted that per tumor, the total amount of chromosomal
alterations, as well as ampliﬁcations was signiﬁcantly lower in the
HPV-related than in the HPV-unrelated tumors (Table 1). This
Table 1 | Alteration in the genome of HNSCCs: genomic aberrations
characteristic for HPV-related OPSCC.
HPV-dependent genomic aberration Reference
3p25, 9p21, 11q13, and 16q12–24 Jung et al. (2010)
3p, 5q, 8p, 11q, 13q, and 20q Wilting et al. (2009)
3p, 5q, 9p, 11q13, 15q, 16q, 18q, and Xp Klussmann et al. (2009)
3p11.2–26.3, 5q11.2–35.2, 9p21.1–24,
11q12.1–13.4, and 18q12.1–23
Smeets et al. (2006)
3q24–qter and 7q11.2–q22 Dahlgren et al. (2003)
ﬁnding is consistent with the assumption that due to the inac-
tivation of the tumor suppressor proteins p53 and pRb by the
viral E6 and E7 oncoproteins, respectively, the number of required
genetic alterations for a malignant phenotype is lower in HPV-
related carcinogenesis. Consequently, a better clinical outcome of
patients with HPV-related tumors could simply be a reﬂection of
less genetic aberrations at the time of treatment. However, speciﬁc
HPV-related genetic alterations have also been identiﬁed (Table 1)
some of which were connected with improved survival. For exam-
ple, 16q loss, which was predominantly identiﬁed in HPV-related
OPSCC, was a strong indicator of favorable outcome and none of
these patients had a tumor recurrence (Klussmann et al., 2009).
Additionally,HPV-negative tumors demonstrate a loss at 18q12.1–
23, in contrast to a gain in HPV-positive tumors (Smeets et al.,
2006). It will be a major challenge in the future to identify can-
didate genes at the affected genomic sites, and to investigate their
contribution to treatment resistance and tumor cell survival in
both patient cohorts as well as preclinical model systems.
To uncover the genetic origin and the mutational landscape
of HNSCC, two recent studies applied gene copy number and
whole exome sequence analysis on specimens of tumor–normal
pairs, including samples from patients with HPV-related tumors
(Agrawal et al., 2011; Stransky et al., 2011). In both studies,
the majority of tumors exhibited a mutational proﬁle consistent
with tobacco exposure, and there were obvious differences in the
genetic landscapes of HPV-related and HPV-negative HNSCCs.
For instance, tumors that were negative for HPV had more muta-
tions than HPV-positive tumors, independently of the smoking
status. This ﬁnding is in line with the data derived by CGH analy-
sis and further conﬁrms major differences in the pathogenesis of
HPV-related and HPV-negative tumors. Furthermore, both stud-
ies observed an inverse correlation between the HPV status and
TP53 mutations, as already shown previously (Wiest et al., 2002;
Westra et al., 2008).
In addition to genomic alteration and gene mutation, aber-
rant DNA methylation is widely recognized as a mechanism in
the progression of HNSCC (Hasegawa et al., 2002; Schmezer and
Plass, 2008), but our knowledge on virus-induced changes in DNA
methylation of the host genome as well as other modes of epige-
netic alterations, as part of the divergent carcinogenic pathway,
is limited. Nevertheless, the identiﬁcation of distinct epigenetic
proﬁles in HPV-related and HPV-negative tumors should pro-
vide clues to novel drug targets for development of individualized
therapeutic strategies. Currently, there is a limited number of stud-
ies which address the differences in epigenetic alteration between
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HPV-related and HPV-negative tumors. Furthermore, the pub-
lished data has largely evaluated changes in promoter methylation
of a limited number of candidate genes, most of which were
selected based on functional relevance in several humanmalignan-
cies (Table 2). A more recent study by Sartor et al. (2011) applied
an integrative approach combining genome-widemethylation and
gene expression proﬁling to characterize the molecular differences
between HPV-related and HPV-negative tumor cell lines. They
found a higher overall DNA methylation in HPV-positive com-
pared to HPV-negative cell lines. This HPV-dependent difference
was consistent with ﬁndings in primary tumor samples and in
line with data from Richards et al. (2009). Moreover, an inverse
correlation between gene promotermethylation and expression of
affected genes was found inHPV-positive cells (Sartor et al., 2011).
Although differentially methylated loci found in tumor cell lines
were signiﬁcantly correlated with primary tumor DNA methyla-
tion levels, a recent study demonstratedmajor changes in theDNA
methylation pattern between cultured cells and primary tumors
(Hennessey et al., 2011). Although these ﬁndings may direct alter-
ations in the epigenome to different disease pathways involved in
HPV-related versus HPV-negative tumors, critical validation in
larger HNSCC tumor sample sets is required.
Global gene expression proﬁling comparing HPV-related and
HPV-negative tumors revealed distinct transcriptome signatures,
reﬂecting underlying heterogeneous somatic, genetic, and epige-
netic alterations. As it would have been expected, all published
studies identiﬁed differentially expressed genes that regulate DNA
replication and cell cycle progression (Slebos et al., 2006;Martinez
et al., 2007; Pyeon et al., 2007; Lohavanichbutr et al., 2009), while
some also describe aberrant regulation of genes involved in viral
defense and immune response (Schlecht et al., 2007; Jung et al.,
2010). It is worth to mention that some differentially expressed
genes are already known to modulate resistance to radiation
and chemotherapeutic drugs, but experimental evidence of their
impact on the favorable outcome of patients with HPV-related
tumors are still missing. Moreover, dysregulation of genes associ-
ated with processes of Natural Killer Cell-mediated cytotoxicity,
activation of the Toll-like receptor, JAK–STAT signaling pathways
(Jung et al., 2010), as well as immune response and inﬂammation
(Schlecht et al., 2007), are of particular interest, assumpting that
themechanisms underlying the clinical differences of HPV-related
and HPV-negative tumors may involve the combined effects of
immune surveillance to viral-speciﬁc tumor antigens, an intact
apoptotic response to radiation, and the absence of widespread
genetic alterations (Pai and Westra, 2009). Yet, the correlation
between altered cytokine and interferon signaling and the HPV
status further supports the conclusion that improved survival of
patients with HPV-related tumors may not only depend on tumor
cell intrinsic features, but also could be due to different activation
of stromal cells within the tumor microenvironment (Figure 2).
MicroRNAs (miRNAs) are small non-coding RNAs,which rep-
resent another mode of gene regulation by inﬂuencing mRNA
translation or decay. Several studies reported altered expression
of distinct miRNAs in the pathogenesis of HNSCC (Babu et al.,
2011). Two recent studies characterized the inﬂuence of HPV on
global miRNA expression in HNSCC cell lines (Wald et al., 2011),
and tumor biopsies of HNSCC patients (Lajer et al., 2011), respec-
tively. Although, the overlap on common deregulated miRNAs is
Table 2 | Summary of genes affected by DNA methylation in HNSCC.
Study Genes/proteins T CL HPV
El-Naggar et al. (1997) CDKN2A 46 11 −
Hasegawa et al. (2002) CDKN2A, DAPK, ECAD, RASSF1A 80 −
Dong et al. (2003) RASSF1A 46 7 +
Wong et al. (2003) CDKN2B, CDKN2A 73 − −
Puri et al. (2005) MLH1, MGMT, CDKN2A 51 − −
Marsit et al. (2006) SFRP family 350 +
Weber et al. (2005) SOCS-1, SOCS-3 94 − −
Dikshit et al. (2007) MGMT, DAPK, E-cadherin 235 − −
Kim et al. (2007) CDKN2A, BIRC5, HIF1A, SKP1, CCNA, CCNB, c-myc, EGFR 52 − +
Martone et al. (2007) MGMT, CDKN2A, DAPK 20 − −
Righini et al. (2007) TIMP3, ECAD, FHIT, APC, DCC, hMLH1,THSB1, RARβ S100A9, CDKN2B, CDKN2A, MGMT, DAPK,
ATM, CASP8, RASSF1
90 − −
Carvalho et al. (2008) DCC, DAPK, TIMP3, ESR, CCNA1, CCND2, MINT1, MINT31, CDH1, AIM1, MGMT, CDKN2A,
PGP9.5, RARB, HIC1, RASSF1A, CALCA, TGFBR2, S100A2, RIZ1, RBM6
211 − −
Marsit et al. (2008) ECAD 340 − +
Taioli et al. (2009) MGMT, CDKN2A, RASSF1A 88 − +
Marsit et al. (2009) 773 genes 68 − −
Munoz-Antonia et al. (2009) TbetaR-I 50 − −
Weiss et al. (2011) TIMP3, CDH1, CDKN2A, DAPK1,TCF21, CD44, MLH1, MGMT, RASSF1A, CCNA1, LARS2, CEBPA 55 − +
Sartor et al. (2011) DNMT3A, CCNA1, CDKN2A, KRT8, RUNX2, IRS, PcG genes − 4 +
Gubanova et al. (2012) SMG-1 34 2 +
Genes/proteins, speciﬁc gene(s) or protein(s; or total number) of genes investigated in each study; T, total number of tumors/patients included in the study; CL,
number of different cell lines included in the study; HPV, consideration of HPV status in the study.
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FIGURE 2 | Intrinsic and extrinsic features of HPV-related HNSCC tumors
potentially involved in the molecular mechanisms underlying improved
disease course. HPV-related tumors have a better survival likely due to the
combined effects of phenomena occurring in epigenome, genome, and
transcriptome. These events drive alternations in intracellular signaling
networks and along with complex interactions of malignant cells with
components of tumor microenvironment including immune cells, they
orchestrate the improved response to treatment and the favorable outcome.
only minor (whichmay be due to the use of cell lines versus tumor
biopsies) increasing our understanding of the virus-targeted miR-
NAs may provide further insight into molecular mechanisms for
the distinct clinical behavior of HPV-related tumors.
CELL INTRINSIC FEATURES OF HPV-POSITIVE TUMOR CELLS
Several intrinsic hallmarks of tumor cells have been described,
including: (i) sustainingproliferative signaling, (ii) evading growth
suppressors, (iii) resisting apoptosis, (iv) enabling unlimited repli-
cation, (v) inducing angiogenesis, and (vi) activating invasion and
metastasis (Hanahan andWeinberg, 2000, 2011). However, which
of these capabilities differ betweenHPV-related andHPV-positive
tumor cells and their likely contribution to the differential clinical
outcome, is still a matter of debate. For instance, while patients
with HPV-related HNSCC respond better to radiotherapy, there
is controversial data concerning whether HPV-related tumor cells
are indeed inherently more radiosensitive than HPV-negative cells
(Pai andWestra, 2009).
Infection by HPV results in over-expression of the viral onco-
proteins and thereby affects many cellular pathways as well as
genome stability. The oncogenic potential of HPV involves the
expression of the viral E6 and E7 oncoproteins, which disrupts
the tumor suppressive p53 and pRB signaling pathways, respec-
tively, and thereby modulate cell cycle progression and survival
of infected keratinocytes (Zur Hausen, 2002). Continued expres-
sion of viral oncogenes is necessary for neoplastic progression
and the malignant phenotype of an HPV-associated tumor. Tran-
scriptionally active viral DNA has been shown to be biologically
and clinically relevant (Figure 1) (Wiest et al., 2002; Fakhry et al.,
2008; Jung et al., 2010). HPV-related HNSCCs have less frequent
p53 or pRBmutations,which often occur inHPV-negative tumors
(Marur et al., 2010). The tumor suppressor p53 acts as a central
mediator of the cellular stress response, including DNA damage
induced apoptosis and cellular senescence by chemotherapy and
ionizing radiation. Therefore, the presence of wild-type p53 in
HPV-related tumors could, at least in part, confer accelerated
chemo- and radiosensitivity compared to HPV-negative tumors
with p53 mutations. Licitra et al. (2006) found that the clinical
behavior of HNSCC patients critically depends on the HPV and
the p53 status. They provided clinical evidence that only patients
with HPV-related tumors and wild-type p53 exhibit an improved
survival, while patients with HPV-related tumors and mutant p53
have an unfavorable outcome, similar to HPV-negative HNSCC
patients. However, in a more recent publication Pang et al. (2011)
showed that expression of the viral E6 oncogene sensitizes tumor
cells to radiation-induced apoptosis, and that the E6∗I, and not the
E6∗II isoform, is sufﬁcient tomediate this effect. Interestingly,E6∗I
was shown to be aweak inhibitor of p53 transactivator activity, and
the study supports a role for E6∗I in the enhanced responsiveness
of HPV-positive OPSCCs to p53-independent radiation-induced
cell death.
The ﬁnding that nuclear Survivin is associated with HPV-
negative compared to HPV-related OPSCC and correlated with
a poor clinical outcome further suggests a fundamental role in cell
death regulation (Preuss et al., 2008). Survivin is an inhibitor of
apoptosis (IAP) and nuclear Survivin is believed to control cell
division, whereas cytoplasmic Survivin is considered cytoprotec-
tive (Stauber et al., 2007). HNSCC cases with nuclear Survivin
and Aurora-B expression exhibited marked malignant behaviors
whereas both Survivin and Aurora-B knockdown inhibited cell
growth and tumor formation (Qi et al., 2010). Furthermore, Sur-
vivin also plays a critical role in mediating resistance to radiation
in part through suppression of apoptosis.
More recently, Gubanova et al. investigated whether the mech-
anism underlying increased sensitivity of HPV-positive tumors to
radiation may be connected to the impaired ability of the can-
cer cells to respond to DNA damage. They found that expression
of SMG-1 (suppressor with morphogenetic effect on genitalia) is
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diminished in HPV-positive tumors due to gene promoter hyper-
methylation (Gubanova et al., 2012). SMG-1 belongs to a family of
phosphoinositide 3-kinase (PI3-kinase)-related kinases (PIKKs)
involved in the maintenance of genome integrity via genotoxic
stress response pathways and plays an important role in the DNA
damage response network (Shiloh, 2003; Brumbaugh et al., 2004;
Gewandter et al., 2011). Low SMG expression correlated with pos-
itive HPV status and improved patient survival, whereas depletion
of SMG-1 in HNSCC cells resulted in their increased sensitivity to
radiation (Gubanova et al., 2012).
The impact of HPVE6andE7oncoproteins in in vitro cell sensi-
tization to radiation remains controversial, since other studies have
suggested that HPV16-positive cervical cancer cells (Padilla et al.,
2002) and HNSCC cells (Hoffmann et al., 2008) as well as HPV-
negative cells with ectopic E6 and E7 expression (Hampson et al.,
2001) are resistant to treatment with cytotoxic drugs and radia-
tion. It is worth noting that increased expression of another IAP
molecule, namely CIAP2, was reported to be signiﬁcantly associ-
atedwithHPV16-relatedHNSCCs (Mansour et al., 2012).Viral E6
oncoprotein has been shown to induce CIAP2 expression through
either the NF-κB or EGFR/PI3K/AKT signaling pathways. CIAP2
confers less sensitivity to apoptosis in HPV16 E6-immortalized
human oral keratinocytes (Yuan et al., 2005; James et al., 2006),
and resistance to cisplatin in HPV-infected lung cancer (Wu et al.,
2010), or 5-FU treatment of HNSCC cell lines (Nagata et al.,
2011). Furthermore, high CIAP2 expression was associated with
poor clinical outcome, at least in patients with oral squamous cell
carcinoma (Nagata et al., 2011).
IMPACT OF THE IMMUNE SYSTEM
Although there is a growing body of in vivo and in vitro data sup-
porting the assumption that HPV-related tumors have a better
survival due to a higher sensitivity to radiation and chemother-
apy, it is difﬁcult to conclusively attribute the improved clinical
outcome only to the intrinsic features of the HPV-infected cells.
It is more likely that a complex paracrine interaction among
intrinsically mediated key pathways and the tumor microenvi-
ronment, including cells of the immune system, may determine
the accelerated sensitivity to either radiation or chemotherapy
(Figure 2). Accordingly, HPV-positive tumors have been postu-
lated to be more susceptible to immune surveillance of tumor-
speciﬁc antigens (Argiris et al., 2008), but so far only a few
studies have explored endogenous host immunity to viral pro-
teins in HNSCC patients, in order to elucidate pathogenetic and
treatment–response mechanisms, and to gain insights into novel
immunotherapeutic strategies.
Cytotoxic therapies including radiation induce potentially
immunogenic cell death, releasing tumor-associated antigens, as
a “danger” signal to the immune system (Shinohara and Maity,
2009). The efﬁcacy of radiotherapy is determined not only by
tumor cell properties, but also endothelial cells and inﬁltrat-
ing immune cells within the tumor environment (Shinohara
and Maity, 2009). High levels of tumor-inﬁltrating lympho-
cytes (TILs) have been identiﬁed as a favorable prognostic bio-
marker in various cancers (Pages et al., 2010), including HNSCC
(Brandwein-Gensler et al., 2005; Lopez-Albaitero et al., 2006;
Uppaluri et al., 2008). However, their exact role on HNSCC,
especially in the context of HPV-related tumors remains to be
elucidated. In this context, Hoffmann et al. found that the fre-
quency of HPV16-E7-speciﬁc T cells in the serum did not dif-
fer between HNSCC patients and healthy controls. However,
higher frequencies of T cells speciﬁc for HPV16-E7 epitopes were
observed in HNSCC patients with HPV-related tumors (Hoff-
mann et al., 2006), which is in line with previous ﬁndings (Albers
et al., 2005). The fact that HPV16-E7 epitopes are apparently
immunogenic raises the question as to why antigen-speciﬁc T
cells in HNSCC patients are unable to eliminate HPV-related
tumors without treatment. One possible explanation was pro-
vided by the ﬁnding that E7-speciﬁc cytotoxic T cells obtained
by in vitro stimulation only recognize human leukocyte anti-
gen HLA-A∗201 positive and HPV16-transformed HNSCC cells
after pretreatment with IFN-gamma (Albers et al., 2005). Fur-
ther analysis demonstrated that this cell line had little or no
expression of critical components of the HLA class I antigen-
processing machinery, which were subsequently up-regulated
upon IFN-gamma treatment. In addition, the antigen-processing
machinery components were also found to be downregulated in
HPV-related tumors compared to adjacent normal epithelium. It
currently remains uncertain as to whether impaired antigen pre-
sentation in HPV-related tumors may be reversed by radiation
or chemotherapy and thereby induces an antitumor immune
response.
In a retrospective study,Rajjoub et al. (2007) reported a positive
correlation between large numbers of TILs (CD3high) and lower
incidence of metastasis at presentation, regardless of HPV status.
However, when the HPV status was taken into account, the cor-
relation between a CD3high count and a lower rate of metastasis
was maintained in HPV-positive but not in HPV-negative patients
(Rajjoub et al., 2007), further supporting the crucial role of the
adaptive immunity in the favorable clinical outcome of HPV-
related tumors. In line with this assumption, the percentage of
circulatingCD8-positive T cells was signiﬁcantly higher in patients
with HPV-related tumors as compared to HPV-negative HNSCC
patients (Wansomet al., 2010). Furthermore this prospective study
revealed a positive correlation between a higher percentage of
CD8-positive T cells and the response to induction chemotherapy
and complete tumor response after chemotherapy. However in a
subsequent study, Wansom et al. (2012) reported that the degree
of T cell inﬁltration in tumor tissue is associated with improved
survival but is independent of the HPV status, similar to previ-
ous ﬁndings (Rajjoub et al., 2007; Wansom et al., 2012). They
concluded that more comprehensive studies with larger num-
bers of patients combined with functional analysis of individual
subsets may be necessary to detect signiﬁcant differences in local
immunity in HPV-related HNSCC.
There is increasing evidence that radiotherapy modulates
immune response and that the underlying mechanism behind
the better prognosis of HPV-positive tumors may be enhanced
immune response following radiotherapy (Vu et al., 2010). In
a recent study, Spanos et al. (2009) found that both HPV-
positive human and murine transformed cell lines cells were
even more resistant to radiation and cisplatin treatment in vitro
compared with HPV-negative counterparts. However, HPV-
positive cells were more sensitive to radiation in a syngeneic
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mouse tumor model, and complete clearance was found at
20Gy, in contrast to HPV-negative cells, which showed per-
sistent growth (Spanos et al., 2009). Similar data were also
obtained upon cisplatin treatment. Intriguingly, neither radi-
ation nor cisplatin therapy cured HPV-positive tumors in
immune-incompetent mice, strongly supporting a crucial role
of the immune system in the therapeutic sensitivity of HPV-
positive tumors. In line with this assumption, Williams et al.
(2009) showed in a syngeneic mouse tumor model that only
HPV-positive tumor cells induce an antigen-speciﬁc antitumor
response, which was mediated by CD4- and CD8-positive T
lymphocytes.
Innate immune cells may also contribute to the favorable clin-
ical outcome of patients with HPV-related OPSCCs. As basal
keratinocytes are the primary target of HPV infection (Feller
et al., 2009), innate immunity represents the ﬁrst line of defense
against invading viruses. Keratinocytes express several pathogen
recognition receptors (PRRs; Pries et al., 2008), and their engage-
ment by pathogen-associated or danger-associated molecular pat-
terns leads to direct activation of the pro-inﬂammatory tran-
scription factors, and/or activation of an anti-viral type I inter-
feron (IFN) response (Rincon-Orozco et al., 2009; Muto et al.,
2011). Several reports highlighted a major impact of viral onco-
proteins on the regulation of pro-inﬂammatory mediators and
anti-viral responses, suggesting that HPV has developed strate-
gies to evade the innate host immunity (Schlecht et al., 2007;
Jung et al., 2010; Karim et al., 2011). For example, expression
of the pro-inﬂammatory molecules S100A8 and S100A9 were
downregulated in HPV-immortalized cells (Dell’oste et al., 2008).
Vice versa, the S100A8/S100A9 protein complex has been shown
to inhibit phosphorylation of the viral E7 oncoprotein by the
casein kinase II and may play an important role in HPV-infected
epithelial cells to counteract the oncogenic activity of E7 (Tugi-
zov et al., 2005). S100A8 (MRP8) and S100A9 (MRP14) belong
to the large family of S100 proteins, which are low molecular
weight proteins sharing conserved structural motifs that consist of
two EF-hand Ca2+-binding domains. S100A8 and S100A9 form
a functional heterodimer (also known as calprotectin) and have
been identiﬁed as important endogenous damage-associatedmol-
ecular pattern proteins that critically contribute to pathological
conditions of acute and chronic inﬂammation, and may therefore
represent a key player in the setting of inﬂammation-associated
carcinogenesis (Gebhardt et al., 2006; Nemeth et al., 2009). It
is worth mentioning, that inﬂammatory signals and the estab-
lishment of a pro-inﬂammatory environment are increasingly
linked to the induction and promotion of tumorigenesis (Balk-
will andMantovani, 2001; Coussens andWerb, 2002; Grivennikov
et al., 2010). One of the most extensively studied signaling net-
work in inﬂammation-associated cancer is the NF-κB pathway
(Ben-Neriah and Karin, 2011), and there is increasing evidence
for its crucial role in the pathogenesis of HNSCC including
HPV-related tumors (Molinolo et al., 2009). Analysis of HPV16-
transformed cell lines revealed that functional components of
the NF-κB signaling pathway were sequestered in the cytoplasm,
or became inactivated by viral E6 and E7 expression, accompa-
nied by reduced expression of cytokines and chemokines (Guess
and McCance, 2005; Havard et al., 2005). However, it will be
a challenge for the future to address the question of whether
changes in pro-inﬂammatory signaling pathways, such as NF-κB,
and the establishment of an activated pro-tumorigenic environ-
ment are causally linked to the increased sensitivity to ther-
apy of patients with HPV-related tumors and their improved
survival.
CONCLUSION AND PERSPECTIVES
Currently, HPV-positive OPSCC dominates the head and neck
oncology landscape, and its escalating incidence has a strong
impact on clinical and translational research. Although it is well
accepted that HPV-related tumors represent a distinct histopatho-
logical and biological entity with a favorable clinical outcome,
we have just now begun to establish the molecular princi-
ples underlying improved survival. As a consequence of mod-
ern genome-wide approaches, our understanding of the fun-
damental mechanisms and biological processes involved in the
pathogenesis of HPV-related and HPV-negative HNSCCs has
rapidly increased. However, most of the functional genomics
data was derived from primary tumor samples largely devoid
of the important information on differences in response to cur-
rent treatment options. Furthermore, the use of several cell
culture and mouse tumor models have produced conﬂicting
results which neither mimic the complex interaction between the
tumor and its activated tumor microenvironment nor the eti-
ology of HPV-related tumors. Hence, there is an urgent need
for an appropriate and more sophisticated preclinical model
system(s).
The mechanisms underlying the clinical differences between
HPV-related andHPV-negative tumorsmay involve the combined
effects of tumor cell intrinsic features and paracrine interactions
between tumor cells and stromal cells of the activated tumor
microenvironment, especially cells of the adaptive and innate
immunity. Unraveling the molecular nature of improved clinical
outcome of HPV-related HNSCC will not only support person-
alized risk assessment but will also unravel new concepts for a
targeted therapy for HNSCC patients with HPV-negative tumors.
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